For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Enova International Inc. (ENVA) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Enova International Inc.
ENVA NYSEEnova International Inc. is a prominent player in the financial services sector, specializing in providing innovative and technology-driven financial solutions. As a leading online financial services provider, Enova offers a diverse range of services, including consumer and small business lending products. The company leverages proprietary analytics, state-of-the-art technology, and advanced machine learning models to evaluate credit and other risks, effectively meeting the demands of its established and growing customer base. Enova's portfolio extends to various industries, significantly impacting consumer finance and small business sectors, by addressing their credit needs through efficient online platforms. Headquartered in Chicago, Illinois, Enova International has made a significant mark in the digital finance landscape, ensuring accessibility to financial resources for underserved markets. Its commitment to responsible lending practices and innovative technology makes it a key player in expanding financial inclusion and enhancing customer experience within the industry.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 11.52
Total Equity: $1.34B
Shares: 26,769,878
Total Debt: $4.50B
Cash: $71.71M
EBITDA: $455.81M
Total Debt: $4.50B
Cash: $71.71M
Revenue: $3.15B
Revenue: $3.15B
Revenue: $3.15B
Total Equity: $1.34B
Tax Rate: 23.1%
Equity: $1.34B
Total Debt: $4.50B
Cash: $71.71M
Current Liabilities: N/A
Long-Term Debt: $4.50B
Total Debt: $4.50B
Total Equity: $1.34B
Shares: 26,769,878
Shares: 26,769,878
CapEx: -$47.14M
Shares: 26,769,878
Stock Price: $253.35
Net Income: $308.39M
Industry Benchmarks
Income Statement (Annual)
Last updated: Jul 30, 2026 7:40pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.7B | $2.1B | $2.7B | $3.2B |
| Cost of Revenue | $260.2M | $734.4M | $1.1B | $1.4B | $1.7B |
| Gross Profit | $947.8M | $1.0B | $1.0B | $1.2B | $1.5B |
| Operating Expenses | $611.2M | $733.6M | $807.8M | $944.7M | $1.1B |
| Operating Income | $336.6M | $268.1M | $227.4M | $294.3M | $406.7M |
| Net Income | $256.3M | $207.4M | $175.1M | $209.4M | $308.4M |
| EBITDA | $374.3M | $306.9M | $265.7M | $341.3M | $455.8M |
| EPS | $7.05 | $6.42 | $5.71 | $7.78 | $12.25 |
| EPS (Diluted) | $6.79 | $6.19 | $5.49 | $7.43 | $11.52 |
Balance Sheet (Annual)
Last updated: Jul 30, 2026 7:16pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $165.5M | $100.2M | $54.4M | $73.9M | $71.7M |
| Total Current Assets | — | — | — | — | — |
| Total Assets | $2.8B | $3.8B | $4.6B | $5.3B | $6.5B |
| Current Liabilities | — | — | — | — | — |
| Long-Term Debt | $1.4B | $2.3B | $2.9B | $3.6B | $4.5B |
| Total Liabilities | $1.7B | $2.6B | $3.3B | $4.1B | $5.1B |
| Total Equity | $1.1B | $1.2B | $1.2B | $1.2B | $1.3B |
| Retained Earnings | $1.1B | $1.3B | $1.5B | $1.7B | $2.0B |
Cash Flow (Annual)
Last updated: Jul 30, 2026 7:40pm (24d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $471.9M | $894.0M | $1.2B | $1.5B | $1.8B |
| Capital Expenditure | -$29.7M | -$43.6M | -$45.2M | -$43.4M | -$47.1M |
| Free Cash Flow | $442.2M | $850.4M | $1.1B | $1.5B | $1.8B |
| Acquisitions (net) | -$29.2M | — | — | — | — |
| Net Debt Issued / (Repaid) | — | — | $396.2M | $500.0M | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$116.7M | -$143.1M | -$153.2M | -$289.3M | -$214.6M |
| Net Change in Cash | -$143.3M | -$47.5M | $199.0M | -$54.8M | $85.2M |
Growth Trends (YoY %)
Last updated: Jul 30, 2026 7:40pm (24d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +43.7% | +22.0% | +25.5% | +18.6% |
| Gross Profit Growth | +5.7% | +3.3% | +19.7% | +20.3% |
| Operating Income Growth | -20.3% | -15.2% | +29.5% | +38.2% |
| Net Income Growth | -19.1% | -15.6% | +19.6% | +47.2% |
| EBITDA Growth | -18.0% | -13.4% | +28.4% | +33.6% |
Deep Analysis
Narrative Economics
market-narrative step).
Claude Reading
The raw numbers on ENVA are unambiguously strong. Revenue has compounded from $1.21B (2021) to $3.15B (2025) — 27% CAGR — and the quarterly trajectory shows acceleration, not deceleration: Q1'26 at $875M is up 17.4% YoY vs Q1'25's $745M, with net margin expanding from 6.3% (Q3'24) to 10.4% (Q1'26). Net income CAGR is 32.7%, and FCF hit $1.77B in 2025 on a $6.3B market cap — that's a 28% FCF yield if you take it at face value. ROE is 23%. At 22x earnings for a business growing EPS ~30%+ with expanding margins, the multiple is not demanding on its face.
But — and this is where I diverge sharply from the synthesis's $591 fair value — you cannot take Enova's FCF at face value. This is a subprime/near-prime consumer lender with $4.5B of debt against $1.34B of equity (3.4x D/E) and $72M of cash. "Operating cash flow" of $1.82B includes loan origination dynamics and provision accounting that are notoriously flattering during benign credit periods and brutal when they turn. The 6.43x accruals ratio the market-forces model flags is a real red flag: when reported earnings materially exceed cash-adjusted earnings in a lender, it usually means loss provisions are lagging charge-offs. ROIC of 5.4% versus ROE of 23% tells the whole story — the 23% ROE is manufactured by leverage, not economic returns. In a credit downturn, that leverage cuts the other way violently.
The synthesis verdict of $591 fair value (+134% upside) is, to be blunt, absurd for a subprime lender. It's applying growth-company DCF logic to a balance-sheet business whose earnings power is capped by credit cycle mean reversion. The narrative model correctly identifies this as a "fallen angel" but wrongly assumes the discount is irrational — the market prices subprime lenders at 8-12x normalized earnings for a reason: peak-cycle EPS is not normalized EPS. Enova earned $256M in 2021, then $207M, $175M, $209M, $308M — that's cyclicality, not compounding. Insiders selling into strength (six sales in ~30 days, zero opportunistic buys) is exactly what you'd expect from management that knows peak credit performance doesn't extrapolate. The pre-flight model gets closer to truth: the market's 22x P/E already reflects strong current results and appropriate skepticism about the through-cycle number.
Where I land: the market-forces "value trap with catastrophic risk" framing overshoots — Enova has genuinely improved its underwriting mix and has real FCF — but the $591 synthesis fair value is model malpractice on a levered subprime book. Fair value is probably $220-$280 depending on where you normalize EPS ($10-12 through-cycle × 22-25x, or $15 peak × 15-18x). At $253, the stock is roughly fairly valued with asymmetric downside if credit turns. A careful contrarian would note that consumer credit metrics (delinquencies, charge-offs) are the only data that matters here and none of it is in this file — that's a critical gap. I dissent from the "undervalued" implication of the synthesis and side closer to the market-forces caution, but without the apocalyptic framing. No position; if you own it, trim into strength given insider behavior; wait for a credit-cycle print or a 30%+ drawdown before getting constructive.
GPT Reading
What stands out first is that the business is performing materially better than the valuation rhetoric implies, but also not nearly well enough to support the more heroic intrinsic value outputs. Enova has grown annual revenue from $2.12B in 2023 to $2.66B in 2024 and $3.15B in 2025, and the quarterly run-rate kept improving into 2026 with Q1 revenue of $875.1M, up 17.4% from $745.5M a year earlier. Net income is accelerating too: from $63.7M in Q4 2024 to $79.0M in Q4 2025 and then $91.1M in Q1 2026. That is a real earnings expansion story, not a statistical mirage. But this is still a lender, and lenders should be read through credit quality, leverage, and durability of spread income, not through software-style multiples. At $6.31B market cap, the stock trades around 20x trailing earnings and roughly 2x sales for a company with a 9.8% 2025 net margin and 12.9% operating margin. Those are good numbers, but not obviously cheap for a heavily levered nonbank credit business.
The biggest distortion in the data is free cash flow. Reported 2025 operating cash flow of $1.82B and free cash flow of $1.77B look spectacular against $308.4M of net income, but for a lender those figures are not comparable to industrial or software FCF because loan origination, repayment timing, and working capital treatment can wildly flatter cash generation in a period. I would not capitalize that $1.77B as if it were distributable owner earnings. The cleaner signal is profitability through the cycle: annual net income recovered from $175.1M in 2023 to $209.4M in 2024 to $308.4M in 2025, after having been $256.3M in 2021 and $207.4M in 2022. That history says earnings power is real, but also cyclical and sensitive. Meanwhile leverage is meaningful: $4.50B of debt against just $71.7M of cash and $1.34B of equity, or 3.37x debt/equity. ROE of 23.1% looks attractive until you remember much of it is balance-sheet leverage rather than extraordinary underlying returns; ROIC at 5.4% is the better sobering metric.
The quarterly trend is the bull case in its strongest form. Revenue has stepped up every quarter from $628.4M in Q2 2024 to $875.1M in Q1 2026, while net margin improved from 6.3% in Q3 2024 to roughly 10% for the last four quarters. That combination—volume growth plus margin repair—is exactly what you want to see in a specialty lender if underwriting and funding are behaving. On that basis, the stock is not overvalued in an obvious way; if 2026 earnings annualize anywhere near the recent $91.1M quarter and continue to grow, the forward P/E is lower than the headline 22x trailing figure. Still, I think the market is broadly right to deny this a premium multiple. EV/EBITDA above 23x and EV/revenue above 3.4x are demanding for a subprime/near-prime online lender facing macro and regulatory risk. This is a good business, but it is not a toll road.
The strongest argument against my caution is simple: the market may still be underestimating operating momentum. Annual revenue is compounding above 20%, recent earnings growth is 47% year over year, gross margin held at 47.3% in 2025, and the latest quarter produced 10.4% net margin—the best in the provided series. If that trajectory persists, today’s $253 price could prove too low because the company would be exiting its prior cyclicality and demonstrating a more scalable underwriting model than skeptics allow. The other strong pushback is that the narrative around “subprime lender catastrophe” is not actually visible in the numbers provided: there is no revenue collapse, no margin blowout, no equity erosion, and no sign yet of earnings rolling over. Insider selling also looks less sinister than advertised, since much of it is tied to option exercises and only modest outright sales. If you believe the recent run-rate is durable, a stock at about 2.15x sales and 22x trailing earnings is not expensive.
What would change my mind is either proof of durability or proof of credit stress. I would turn more bullish if the next two quarters sustain revenue above $900M and net margin at or above 10%, taking annualized earnings power toward $360M-$400M without leverage rising further; at that point, the current price would look merely fair to slightly cheap. I would turn decisively bearish if revenue keeps growing but net income slips back toward the $40M-$60M quarterly zone seen in weaker periods, because that would suggest credit costs are catching up and the multiple is far too high for a cyclical lender. I would also want to see whether debt continues to climb faster than equity and whether cash flow remains “strong” once normalized for lending balance-sheet movements. For now, I see a solid operator priced about where a solid but leveraged credit business should trade—not the wipeout some models imply, and not the screaming bargain others claim.
Grok Reading
Enova’s numbers describe a scaled, cash-compounding credit platform that the market refuses to underwrite at face value. Revenue has compounded from $1.21B in 2021 to $3.15B in 2025 (22% CAGR), with the latest quarter at $875M still accelerating sequentially from $745M a year earlier. Net income flipped from a trough of $175M in 2023 to $308M in 2025, and trailing quarterly NI margins have stabilized in a tight 9.4–10.4% band after the 6.3% soft patch in late 2024. The real tell is cash: $1.82B operating cash flow and $1.77B free cash flow against a $6.31B equity value implies a mid-to-high-20s FCF yield even after a modest haircut for lending-specific working-capital noise. That is not the cash profile of a business the market should be pricing at 22× earnings and 2.2× sales while ROE sits at 23%. The story the ledger tells is simple: originations and collections are still outrunning charge-offs, the cost base is scaling, and the equity is being levered productively.
The balance-sheet optics look terrifying in isolation—$4.50B of debt, $72M of cash, 3.37× debt-to-equity—but for a consumer and small-business lender this is the product, not a distress signal. ROIC of 5.4% and ROA of 4.8% are exactly what you expect when the asset base is mostly loans funded by warehouse and ABS facilities; the 23% ROE is the more relevant capital-efficiency metric and it is healthy. Gross margin has compressed from the mid-70s in 2021 to 47% as the mix shifted toward lower-spread products, yet operating margin held at 12.9% and absolute operating profit grew from $227M to $407M over two years. That is evidence of operating leverage, not margin collapse. Against the prior models’ “fair value near $592” I am less interested in the precise DCF output than in the direction: every fundamental screen that is not a credit-cycle scare screen says the stock is cheap at $253.
The strongest counter-case is that this is precisely the setup that precedes a credit-cycle wipeout. Insiders have been consistent sellers through mid-2026 (repeated option exercises immediately flipped into open-market sales totaling well over 90k shares in the visible window), the accruals flag at 6.4× is a classic warning that earnings quality may be running ahead of cash reality, and a subprime/near-prime book levered 3.4× equity will see equity value vaporize if unemployment rises or regulatory caps tighten. The reverse-DCF implication of roughly –10% perpetual FCF decline that the market is embedding is not irrational if you believe charge-offs are about to gap higher; history is littered with lenders that printed 20%+ FCF yields right up until the quarter they didn’t. I weigh this differently because the sequential revenue and margin data through Q1 2026 show no deterioration yet, FCF conversion remains exceptional, and the 18–22% top-line growth is still being delivered while the stock trades at a 50%+ discount to even conservative intrinsic-value estimates. The risk is real; the current price already capitalizes a severe outcome.
I would flip to a neutral or outright bearish stance if two consecutive quarters showed net charge-off rates spiking above historical mid-cycle levels while revenue growth decelerated below 10%, or if management guided to a material tightening of underwriting that cut originations enough to shrink the loan book. A regulatory action that caps APRs or restricts online origination channels in core states would also break the thesis. Until one of those appears, the gap between $253 and the cash-generation power of the franchise is too wide to ignore.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Prediction unavailable. The value lens (ext-lens-value) has not run for ENVA — needed for buy-below + conviction.